- Home
- Publications
- Publication Search
- Publication Details
Title
Apremilast: A Review in Psoriasis and Psoriatic Arthritis
Authors
Keywords
Psoriasis, Placebo Recipient, Plaque Psoriasis, Certolizumab Pegol, Biologic DMARDs
Journal
DRUGS
Volume 75, Issue 12, Pages 1393-1403
Publisher
Springer Nature
Online
2015-07-28
DOI
10.1007/s40265-015-0439-1
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- THU0420 Long-Term (104-Week) Efficacy and Safety Profile of Apremilast, An Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis: Results from a Phase III, Randomised, Controlled Trial and Open-Label Extension (Palace 1)
- (2015) A. Kavanaugh et al. ANNALS OF THE RHEUMATIC DISEASES
- SAT0568 Long-Term Work Productivity Improvement Associated with Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis: Pooled Analysis of 3 Phase 3 Studies
- (2015) F. Zhang et al. ANNALS OF THE RHEUMATIC DISEASES
- THU0416 Disease Activity and Safety During Long-Term (104-Week) Treatment with Apremilast, An Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis: Results from a Phase III, Randomized, Controlled Trial and Open-Label Extension (Palace 3)
- (2015) C. Edwards et al. ANNALS OF THE RHEUMATIC DISEASES
- THU0432 Long-Term (104-Week) Safety Profile of Apremilast, An Oral Phosphodiesterase 4 Inhibitor, In Patients with Psoriatic Arthritis: Pooled Safety Analysis of Three Phase 3, Randomized, Controlled Trials
- (2015) P. Mease et al. ANNALS OF THE RHEUMATIC DISEASES
- THU0413 Apremilast, An Oral Phosphodiesterase 4 Inhibitor: Improvements in Nail and Scalp Psoriasis and Psoriasis Area and Severity Index in Patients with Moderate to Severe Plaque Psoriasis (Esteem 1 and 2)
- (2015) K. Papp et al. ANNALS OF THE RHEUMATIC DISEASES
- Longterm (52-week) Results of a Phase III Randomized, Controlled Trial of Apremilast in Patients with Psoriatic Arthritis
- (2015) A. Kavanaugh et al. JOURNAL OF RHEUMATOLOGY
- Estimating the proportion of patients who achieve a clinically meaningful benefit from apremilast therapy in the ESTEEM trials
- (2015) JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Change in weight with apremilast, an oral phosphodiesterase 4 inhibitor: Pooled analysis of the ESTEEM 1 and ESTEEM 2 trials
- (2015) JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Two-year safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate to severe plaque psoriasis: Results from a phase 3, randomized, controlled trial (ESTEEM 1)
- (2015) JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- The impact of apremilast therapy on work productivity among patients with moderate to severe plaque psoriasis: Pooled analysis of 2 phase 3 studies
- (2015) JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Comparative efficacy of methotrexate versus apremilast for methotrexate-naïve psoriasis patients: An indirect comparison
- (2015) JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1)
- (2015) Kim Papp et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- The Pharmacodynamic Impact of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, on Circulating Levels of Inflammatory Biomarkers in Patients with Psoriatic Arthritis: Substudy Results from a Phase III, Randomized, Placebo-Controlled Trial (PALACE 1)
- (2015) Peter H. Schafer et al. Journal of Immunology Research
- OP0104 Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis Including Current Skin Involvement: Results of a Phase 3, Randomized, Controlled Trial
- (2014) C. Birbara et al. ANNALS OF THE RHEUMATIC DISEASES
- AB0758 Change in Weight from Baseline during the Palace Clinical Trial Program with Apremilast, an Oral Phosphodiesterase 4 Inhibitor: Pooled Results from 3 Phase 3, Randomized, Controlled Trials
- (2014) P. Mease et al. ANNALS OF THE RHEUMATIC DISEASES
- OP0078 Apremilast, an Oral Phosphodiesterase 4 Inhibitor, is Associated with Long-Term (52-WEEK) Improvement in Measures of Disease Activity in Patients with Psoriatic Arthritis: Results from 3 Phase 3, Randomized, Controlled Trials
- (2014) A. Kavanaugh et al. ANNALS OF THE RHEUMATIC DISEASES
- Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor
- (2014) Arthur Kavanaugh et al. ANNALS OF THE RHEUMATIC DISEASES
- Apremilast is a selective PDE4 inhibitor with regulatory effects on innate immunity
- (2014) P.H. Schafer et al. CELLULAR SIGNALLING
- Work Productivity Improvement Associated With Apremilast, An Oral Phosphodiesterase 4 Inhibitor, in Patients With Psoriatic Arthritis Results Of A Phase 3, Randomized, Controlled Trial
- (2014) F. Zhang et al. VALUE IN HEALTH
- Therapeutic Strategies in Psoriasis Patients with Psoriatic Arthritis: Focus on New Agents
- (2013) Emily Yiping Gan et al. BIODRUGS
- Treatment of Psoriasis and Psoriatic Arthritis
- (2013) Marina Papoutsaki et al. BIODRUGS
- The 2012 BSR and BHPR guideline for the treatment of psoriatic arthritis with biologics
- (2013) Laura C. Coates et al. RHEUMATOLOGY
- Oral apremilast in the treatment of active psoriatic arthritis: Results of a multicenter, randomized, double-blind, placebo-controlled study
- (2012) Georg Schett et al. ARTHRITIS AND RHEUMATISM
- Efficacy and safety of apremilast in subjects with moderate to severe plaque psoriasis: results from a phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison study
- (2012) K.A. Papp et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial
- (2012) Kim Papp et al. LANCET
- European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies
- (2011) L Gossec et al. ANNALS OF THE RHEUMATIC DISEASES
- Disposition, metabolism and mass balance of [14C]apremilast following oral administration
- (2011) Matthew Hoffmann et al. XENOBIOTICA
- Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis
- (2009) PH Schafer et al. BRITISH JOURNAL OF PHARMACOLOGY
- An open-label, single-arm pilot study in patients with severe plaque-type psoriasis treated with an oral anti-inflammatory agent, apremilast
- (2008) A. B. Gottlieb et al. CURRENT MEDICAL RESEARCH AND OPINION
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search